Clinical Study

Nrg-Gy018- A Phase III Randomized, Placebo-Controlled Study Of Pembrolizumab (Mk-3475, Nsc #776864) In Addition To Paclitaxel And Carboplatin For Measurable Stage III Or Iva, Stage Ivb Or Recurrent Endometrial Cancerchemoradiation Plus Atezolizumab

Posted Date: Mar 6, 2020

  • Investigator: Amanda Jackson
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to evaluate the progression free survival of pembrolizumab in combination with paclitaxel and carboplatin in patients with advanced stage (measurable stage III or IVA), stage IVB and recurrent endometrial cancer.

Criteria:

To Be Eligible: Measurable Stage Iii, Iva, Or Ivb, Or Recurrent (With Or Without Measurable Disease) Endometrial Cancer. Ecog 0-2, Normal Tsh Levels, No Hypersensitivities To Study Drugs Or Excipients, No Immunodeficiency, Any Active Or Uncontrolled Illness Or Infection That May Impact Study Results

Keywords:

Endometrial Cancer

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.